These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16212139)

  • 1. Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.
    Adami S; Pavelka K; Cline GA; Hosterman MA; Barton IP; Cohen SB; Bensen WG
    Mayo Clin Proc; 2005 Oct; 80(10):1278-85. PubMed ID: 16212139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
    Taggart H; Bolognese MA; Lindsay R; Ettinger MP; Mulder H; Josse RG; Roberts A; Zippel H; Adami S; Ernst TF; Stevens KP
    Mayo Clin Proc; 2002 Mar; 77(3):262-70. PubMed ID: 11888030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity.
    Baker DE
    Rev Gastroenterol Disord; 2002; 2(1):20-33. PubMed ID: 12122976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae.
    Lanza F; Schwartz H; Sahba B; Malaty HM; Musliner T; Reyes R; Quan H; Graham DY
    Am J Gastroenterol; 2000 Nov; 95(11):3112-7. PubMed ID: 11095326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
    Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J
    Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group.
    Bocanegra TS; Weaver AL; Tindall EA; Sikes DH; Ball JA; Wallemark CB; Geis GS; Fort JG
    J Rheumatol; 1998 Aug; 25(8):1602-11. PubMed ID: 9712107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Delmas PD; McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S
    Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Cohen S; Levy RM; Keller M; Boling E; Emkey RD; Greenwald M; Zizic TM; Wallach S; Sewell KL; Lukert BP; Axelrod DW; Chines AA
    Arthritis Rheum; 1999 Nov; 42(11):2309-18. PubMed ID: 10555025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial.
    Frakes EP; Risser RC; Ball TD; Hochberg MC; Wohlreich MM
    Curr Med Res Opin; 2011 Dec; 27(12):2361-72. PubMed ID: 22017192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of risedronate in postmenopausal women intolerant of alendronate.
    Adachi JD; Adami S; Miller PD; Olszynski WP; Kendler DL; Silverman SL; Licata AA; Li Z; Gomez-Panzani E
    Aging (Milano); 2001 Oct; 13(5):347-54. PubMed ID: 11820707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis.
    Temple AR; Benson GD; Zinsenheim JR; Schweinle JE
    Clin Ther; 2006 Feb; 28(2):222-35. PubMed ID: 16678643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173].
    Spector TD; Conaghan PG; Buckland-Wright JC; Garnero P; Cline GA; Beary JF; Valent DJ; Meyer JM
    Arthritis Res Ther; 2005; 7(3):R625-33. PubMed ID: 15899049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
    Bishop N; Adami S; Ahmed SF; Antón J; Arundel P; Burren CP; Devogelaer JP; Hangartner T; Hosszú E; Lane JM; Lorenc R; Mäkitie O; Munns CF; Paredes A; Pavlov H; Plotkin H; Raggio CL; Reyes ML; Schoenau E; Semler O; Sillence DO; Steiner RD
    Lancet; 2013 Oct; 382(9902):1424-32. PubMed ID: 23927913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
    Ilter E; Karalok H; Tufekci EC; Batur O
    Climacteric; 2006 Apr; 9(2):129-34. PubMed ID: 16698659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.